tiprankstipranks
Trending News
More News >
Elekta AB (SE:EKTA.B)
:EKTA.B

Elekta AB (EKTA.B) AI Stock Analysis

Compare
2 Followers

Top Page

SE

Elekta AB

(LSE:EKTA.B)

Rating:64Neutral
Price Target:
kr54.00
▲(10.16%Upside)
Elekta AB's stock score is influenced primarily by its solid financial performance, despite some cash flow constraints. Technical analysis suggests mixed signals with potential bearish trends, while the high P/E ratio indicates overvaluation. The decent dividend yield provides some support against valuation concerns.

Elekta AB (EKTA.B) vs. iShares MSCI Sweden ETF (EWD)

Elekta AB Business Overview & Revenue Model

Company DescriptionElekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
How the Company Makes MoneyElekta AB generates revenue primarily through the sale and servicing of its medical devices and software solutions to hospitals and clinics worldwide. The company's key revenue streams include the sale of linear accelerators, which are used for radiation therapy, and associated software licenses for treatment planning and management. Elekta also earns revenue from long-term service agreements, offering maintenance and support for its equipment. Significant partnerships with healthcare providers and research institutions enhance its product offerings and market reach, contributing to its earnings. Additionally, Elekta's focus on innovation and technology advancements ensures a steady demand for its products in the oncology treatment space.

Elekta AB Financial Statement Overview

Summary
Elekta AB has strong profitability and a solid balance sheet, with a noteworthy ability to generate cash. However, recent capital expenditures have slightly strained free cash flow, and a minor decline in revenue growth could pose challenges.
Income Statement
74
Positive
Elekta AB demonstrates solid profitability with a gross profit margin of approximately 36.5% and a net profit margin of 5.8% in the TTM period. Despite a slight dip in total revenue from the previous annual report, the company has maintained stable EBIT and EBITDA margins of around 10% and 15.3%, respectively. The revenue growth from 2021 to 2024 indicates a positive trend, although the TTM period shows a minor decline, suggesting potential challenges in maintaining growth momentum.
Balance Sheet
80
Positive
The company exhibits a healthy balance sheet with a debt-to-equity ratio of about 0.82, indicating a balanced leverage position. The equity ratio stands at approximately 32.7%, reflecting a strong equity base. Furthermore, the return on equity (ROE) of 9.6% in the TTM period signals efficient use of equity to generate profits, albeit slightly lower than previous years.
Cash Flow
68
Positive
Elekta AB's cash flow statement reveals a robust operating cash flow to net income ratio of 2.29, highlighting strong cash generation relative to net income. However, free cash flow decreased in the TTM period due to increased capital expenditures, resulting in a lower free cash flow to net income ratio of 0.65. This indicates potential pressure on cash reserves for future investments.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
17.88B18.12B16.87B14.55B13.76B14.60B
Gross Profit
6.52B6.78B6.35B5.44B5.61B6.14B
EBIT
1.78B2.04B1.43B1.64B1.91B1.66B
EBITDA
2.74B3.29B2.57B2.74B3.13B2.99B
Net Income Common Stockholders
1.04B1.30B943.00M1.15B1.25B1.08B
Balance SheetCash, Cash Equivalents and Short-Term Investments
3.58B2.78B3.27B3.07B4.40B6.46B
Total Assets
32.95B31.41B29.61B26.30B24.84B28.41B
Total Debt
8.86B7.25B6.67B5.70B6.24B9.36B
Net Debt
5.28B4.47B3.40B2.63B1.84B2.96B
Total Liabilities
22.12B20.63B19.88B17.39B16.65B20.30B
Stockholders Equity
10.78B10.77B9.73B8.91B8.20B8.11B
Cash FlowFree Cash Flow
679.00M817.00M400.00M450.00M1.71B252.00M
Operating Cash Flow
2.38B2.46B1.96B1.86B2.55B1.01B
Investing Cash Flow
-1.80B-1.92B-1.61B-1.65B-613.00M-1.30B
Financing Cash Flow
516.00M-1.10B-129.00M-1.73B-3.60B2.62B

Elekta AB Technical Analysis

Technical Analysis Sentiment
Negative
Last Price49.02
Price Trends
50DMA
49.87
Negative
100DMA
55.30
Negative
200DMA
59.67
Negative
Market Momentum
MACD
-0.39
Positive
RSI
45.06
Neutral
STOCH
46.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:EKTA.B, the sentiment is Negative. The current price of 49.02 is below the 20-day moving average (MA) of 50.75, below the 50-day MA of 49.87, and below the 200-day MA of 59.67, indicating a bearish trend. The MACD of -0.39 indicates Positive momentum. The RSI at 45.06 is Neutral, neither overbought nor oversold. The STOCH value of 46.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:EKTA.B.

Elekta AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
kr18.97B80.372.43%4.83%-0.57%-81.68%
54
Neutral
$5.38B3.31-45.11%3.29%16.82%0.04%
DE24C
€106.22M38.9910.11%
DE6Y1
€41.18M-19.17%
DE7AC
€23.53M-88.97%
€5.86M
€98.03M-5.61%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:EKTA.B
Elekta AB
49.02
-13.99
-22.20%
DE:24C
C-Rad AB Class B
3.24
-0.54
-14.29%
DE:6Y1
Integrum AB Class B
1.88
-2.79
-59.74%
DE:7AC
Acarix AB
0.02
>-0.01
-33.33%
DE:7820
Scandinavian Real Heart AB
1.10
-1.54
-58.33%
DE:7D2A
Sedana Medical AB
0.97
-1.22
-55.71%

Elekta AB Corporate Events

Elekta AB Reports Strong Q4 Performance with Best Gross Margin in Five Years
May 28, 2025

Elekta AB reported a 6% increase in net sales for the fourth quarter of 2024/25 at constant exchange rates, driven by strong performance in Europe and APAC, and a 3% increase in reported sales. The company achieved its best fourth-quarter gross margin in five years at 40.3%, supported by price increases, product launches, and a solid performance of its Elekta Evo linear accelerator and Elekta ONE software suite. Despite a non-cash impairment of SEK 1,064 M due to discontinued R&D projects, Elekta maintained a strong book-to-bill ratio and improved cash flow. The company expects continued sales growth and margin improvements, aiming to reach pre-pandemic levels, while its products have received positive feedback from healthcare providers.

The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK67.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

Elekta to Present Fiscal Year 2024/25 Developments
May 13, 2025

Elekta has announced a presentation for its fiscal year 2024/25, scheduled for May 28, where the company’s Acting President and CEO, Jonas Bolander, along with CFO Tobias Hägglöv, will discuss the company’s development. The event, which includes a live webcast and Q&A session, reflects Elekta’s commitment to transparency and engagement with analysts and investors, potentially impacting its market positioning and stakeholder relations.

The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK67.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.